Dr. Reddy’s Laboratories (DRREDDY) Q4 22/23 earnings summary

Executive summary

• FY23 delivered record sales and EBITDA, supported by double-digit growth and new product launches; healthy EBITDA and ROCE, with net cash surplus of Rs. 5,046 Cr.

• Strategic licensing and acquisitions advanced Horizon 1 and Horizon 2 businesses; productivity initiatives continued alongside investment for sustainable growth.

Financial highlights

• FY23 revenue Rs. 24,588 Cr, up 15% YoY; EBITDA Rs. 7,308 Cr, up 42%; PBT Rs. 6,037 Cr, up 87%; PAT Rs. 4,507 Cr, up 91%.

• Q4 FY23 revenue Rs. 6,297 Cr, up 16% YoY and down 7% QoQ; EBITDA Rs. 1,631 Cr, up 26% YoY and down 17% QoQ.

• Q4 PBT Rs. 1,326 Cr, up 434% YoY; PAT Rs. 959 Cr, up 996% YoY, with both comparisons affected by impairments in current and prior periods.

Outlook and guidance

• Key priorities: build a robust product pipeline, strengthen people, digital and process capabilities, invest in Horizon 2 growth avenues, drive productivity and integrate ESG.

• Continued investment in R&D and productivity was positioned as supporting sustainable growth.